During a live event, Jan Drappatz, MD, and participants discussed which patients with glioma should receive IDH inhibitors and what next steps could identify who will benefit.
Targeted Inhibition for Grade 2 IDH-Mutant Glioma
During a live event, Jan Drappatz, MD, surveyed participants on the rationale for their choice of treatment for a 39-year-old patient with grade 2 astrocytoma.